GAS6 in systemic inflammatory diseases: with and without infection by Hurtado Villarejo, Begoña & García de Frutos, Pablo
Since its discovery in 1929 as the ‘Koagulations-Vitamin’ 
by Henrik Dam, the main role assigned to vitamin K has 
been linked to main taining hemostasis. Vitamin K 
inhibitors have been used in the clinic as anticoagulants 
since the 1950s. Vitamin K is an essential cofactor in the 
post-transcriptional modiﬁ cation of glutamic residues of 
a small number of proteins in the human genome. 
Although the majority of these vitamin K-dependent 
proteins are part of the coagulation cascade or its 
regulators, others are involved in diﬀ erent processes. Th e 
view of vitamin K function is therefore now broader, and 
recent research has demon strated a wide range of 
functions associated with vitamin K-dependent proteins; 
for instance, their implication in calcium homeostasis in 
the bone and other tissues. Furthermore, vitamin K-
dependent proteins are present in invertebrates and other 
species lacking a coagulation cascade.
A later addition to these functions has been produced 
by studies on GAS6, the subject of the recent report by 
Ekman and colleagues [1]. GAS6 and the highly similar 
anticoagulant protein S were discovered to be ligands of a 
family of formerly orphan receptor protein tyrosine 
kinases, the TAM family [2,3]. Th e function of this family 
of receptors was soon recognized to be important in 
mechanisms of defense against injuries, especially 
through their action as regulators of inﬂ ammation, apop-
totic cell clearance and platelet–endothelial activation 
[4-7].
Owing to the low concentration of GAS6 in plasma and 
its similarity to protein S, which is 1,000-fold more 
concentrated, creating a reliable test to detect its concen-
tra tion under diﬀ erent disease conditions has been a 
challenge. Despite these diﬃ  culties, several groups have 
reported that GAS6 acts as an acute-phase reactant, 
increasing its concentration during sepsis [8,9]. Th e 
present study by Ekman and colleagues provides detailed 
evidence of this increase by comparing at the same time 
patients with diﬀ erent diagnoses related to septicemia – 
including severe sepsis, sepsis, systemic inﬂ ammatory 
response syn drome without infection, and veriﬁ ed 
infection – blood donors, systemic inﬂ ammatory res ponse 
syndrome patients with infections, and patients without 
systemic inﬂ ammatory response syndrome as controls. 
Furthermore, the study determines the concen tration of 
soluble Axl, a processed form of the receptor that is 
present in plasma at molar excess compared with GAS6 
and that seems to capture most of the GAS6, forming a 
stable complex [10]. Previous studies have clearly 
established that GAS6 is increased in septic patients, and 
its concentration correlates with disease severity [8,9].
In the present study, the authors show that plasma 
GAS6 increased in all conditions studied, irrespective of 
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the presence of infection. Other conditions with an 
important activation of inﬂ ammation, such as pancrea-
titis, also show increased levels of GAS6 [11]. Taken 
together, these data suggest that GAS6 would be a general 
marker of inﬂ am matory conditions rather than a speciﬁ c 
marker for sepsis. Th is hypothesis would ﬁ t well with the 
view of the TAM receptor system as a brake for the 
innate immunity [12]. GAS6 itself shows anti-inﬂ am ma-
tory properties in certain cells, reducing cytokine 
synthesis [13], but could also orches trate the course of 
inﬂ am mation by favoring platelet and leukocyte inter-
actions with the endothelium [7].
Th e study of the role of GAS6 and its TAM receptors in 
human pathology has just begun. Recent developments 
include assays to test the genetic variability of the GAS6 
gene [14] and to test the TAM receptors in the human 
genome [15]. Th ese assays would allow correlating 
plasma parameters with the genetic background, leading 
to a deeper understanding of the possible role of the 
GAS6–TAM system in sepsis.
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